Hope for rare amyloidosis: new combo shows promise in Late-Stage trial
Disease control
Terminated
This study tested a new drug, ixazomib, combined with dexamethasone against standard treatments for people with relapsed or refractory AL amyloidosis, a rare disease where abnormal proteins damage organs. The trial included 177 adults and aimed to see if the new combination impro…
Phase: PHASE3 • Sponsor: Millennium Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC